Disparate in vivo efficacy of FTY720 in xenograft models of Philadelphia positive and negative B-lineage acute lymphoblastic leukemia
about
The Basic Biology of PP2A in Hematologic Cells and MalignanciesQuantification of OSU-2S, a novel derivative of FTY720, in mouse plasma by liquid chromatography-tandem mass spectrometry.Efficacy of dual PI-3K and mTOR inhibitors in vitro and in vivo in acute lymphoblastic leukemiaDestabilisation of dimeric 14-3-3 proteins as a novel approach to anti-cancer therapeutics.PP2A Counterbalances Phosphorylation of pRB and Mitotic Proteins by Multiple CDKs: Potential Implications for PP2A Disruption in CancerOncogenic properties of sphingosine kinases in haematological malignancies.Role of Sphingolipids and Metabolizing Enzymes in Hematological Malignancies.Mouse models for pre-clinical drug testing in leukemia.Acute Lymphoblastic Leukemia in a Man Treated With Fingolimod for Relapsing Multiple Sclerosis.Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors.PKR negatively regulates leukemia progression in association with PP2A activation, Bcl-2 inhibition and increased apoptosis.Regulation of the bone marrow microenvironment by G-CSF: Effects of G-CSF on acute lymphoblastic leukaemia.Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations.
P2860
Q28088697-BF92C078-CE9E-4C27-9751-9BA8F62E13D7Q34266856-F4841EE7-3F3F-4905-887C-0FD5E511D248Q34786480-7841E207-D5EF-48D9-8E0A-66F6F411E161Q35987404-00B941F7-18F0-4CD8-BA09-F42A67BD9C7CQ36796453-4B611ECD-6CCD-475E-A085-5327FD72C6AAQ38092176-611F2B3E-C8A9-4422-9B7E-01FF3BD2BED4Q38495744-816163D4-6DF3-4112-B4F1-DCABFA65EE0DQ38937610-380CD51E-0BC8-4E78-9D21-1EAE3417C564Q38957915-6FAE94FC-19B8-40B4-8AD7-29308F947C84Q40859498-FA772B0B-9851-45C0-96F1-A641A97229F4Q42959284-A451FE63-AF30-4435-BBE3-4809A9C5AC9CQ45914089-4FCABC0B-75EB-4E2F-9BB8-C9B7B24D2D03Q52774797-6DD25100-0EF6-4F11-AB19-7C9E25D02BFE
P2860
Disparate in vivo efficacy of FTY720 in xenograft models of Philadelphia positive and negative B-lineage acute lymphoblastic leukemia
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Disparate in vivo efficacy of ...... e acute lymphoblastic leukemia
@ast
Disparate in vivo efficacy of ...... e acute lymphoblastic leukemia
@en
Disparate in vivo efficacy of ...... e acute lymphoblastic leukemia
@nl
type
label
Disparate in vivo efficacy of ...... e acute lymphoblastic leukemia
@ast
Disparate in vivo efficacy of ...... e acute lymphoblastic leukemia
@en
Disparate in vivo efficacy of ...... e acute lymphoblastic leukemia
@nl
prefLabel
Disparate in vivo efficacy of ...... e acute lymphoblastic leukemia
@ast
Disparate in vivo efficacy of ...... e acute lymphoblastic leukemia
@en
Disparate in vivo efficacy of ...... e acute lymphoblastic leukemia
@nl
P2093
P2860
P50
P3181
P1433
P1476
Disparate in vivo efficacy of ...... e acute lymphoblastic leukemia
@en
P2093
John Hewson
Kenneth F Bradstock
Linda J Bendall
Rachael A Papa
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0036429
P407
P577
2012-05-03T00:00:00Z